CoChat

Update on the Management of Diabetic Neuropathy

Open access
Ang, Lynn, Cowdin, Nathan, Mizokami-Stout, Kara, Pop-Busui, Rodica · 2018 · Diabetes Spectrum

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Abstract

IN BRIEF Distal symmetric polyneuropathy (DSPN) and diabetic autonomic neuropathies, particularly cardiovascular autonomic neuropathy (CAN), are prevalent diabetes complications with high morbidity, mortality, and amputation risks. The diagnosis of DSPN is principally a clinical one based on the presence of typical symptoms combined with symmetrical, distal-to-proximal stocking-glove sensory loss. CAN is an independent risk factor for cardiovascular mortality, arrhythmia, silent ischemia, major cardiovascular events, and myocardial dysfunction. Screening for CAN in high-risk patients is recommended. Symptoms of gastroparesis are nonspecific and do not correspond with its severity. Diagnosis of gastroparesis should exclude other factors well documented to affect gastric emptying such as hyperglycemia, hypoglycemia, and certain medications. There is a lack of treatment options targeting the neuropathic disease state. Managing neuropathic pain also remains a challenge. Given the high risk of addiction, abuse, psychosocial issues, and mortality, opioids are not recommended as first-, second-, or third-line agents for treating painful DSPN.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/ds18-0036

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1. Algorithm for management of patients with pain due to DSPN. *Pregabalin is FDA-approved for painful DSPN, whereas gabapentin is not. Pharmacokinetic profile, spectrum of AEs and drug interactions, comorbidities, and costs should be considered in selecting the agent of choice. **Duloxetine is FDA-approved for painful DSPN, whereas venlafaxine is not. Pharmacokinetic profile, spectrum of AEs, drug interactions, comorbidities, and costs should be considered in selecting the agent of choice. #None is FDA-approved for painful DSPN. Spectrum of AEs, drug interactions, and comorbidities should be considered in selecting these agents. Reprinted with permission from ref. 1.
FIGURE 1. Algorithm for management of patients with pain due to DSPN. *Pregabalin is FDA-approved for painful DSPN, whereas gabapentin is not. Pharmacokinetic profile, spectrum of AEs and drug interactions, comorbidities, and costs should be considered in selecting the agent of choice. **Duloxetine is FDA-approved for painful DSPN, whereas venlafaxine is not. Pharmacokinetic profile, spectrum of AEs, drug interactions, comorbidities, and costs should be considered in selecting the agent of choice. #None is FDA-approved for painful DSPN. Spectrum of AEs, drug interactions, and comorbidities should be considered in selecting these agents. Reprinted with permission from ref. 1.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Jaiswal, 2014, Prevalence and correlates of cardiovascular autonomic neuropathy in youth with type 1 diabetes: SEARCH for Diabetes in Youth Study [Abstract], Diabetes, 63, A145

Cited by

See all 55

Metadata

Authors
Ang, L., Cowdin, N., Mizokami-Stout, K., & Pop-Busui, R.
Affiliations
  • University of Michigan (US)
  • Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
Venue
Diabetes Spectrum
Published
2018-08-01
Volume
31
Issue
3
Pages
224-233
ISSN
  • 1040-9165 (ISSN-L)
  • 1944-7353
OpenAlex
W2886645622
Cited by
55
References
61
Citations by year
2026: 3 · 2025: 8 · 2024: 11 · 2023: 9 · 2022: 8 · 2021: 4 · 2020: 8 · 2019: 4
FWCI
2.75
Type
journal article
Language
en
Open access
Locations
  • Diabetes Spectrum (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092926)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
diabetic neuropathy, distal symmetric polyneuropathy, diabetic autonomic neuropathy, cardiac autonomic neuropathy, gastroparesis, neuropathic pain, opioid use, amputation risk, cardiovascular mortality

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.